2022 Antibody Therapeutic Conference (ATC)
Extended Application of Antibody
Time: 2022.11.15 TUE
Venue: National Biotechnology Research Park, Nangang. International Convention Hall (Building C)
Agenda:
Time | Activities | Speaker |
9:00-9:30 | Registration |
|
9:30-9:40 | Welcome Remarks | Chung-Hsiun Wu, Ph.D. 吳忠勳 President, Development Center for Biotechology (DCB) 台灣抗體協會理事長/生物技術開發中心執行長 |
9:40-9:50 | Moderator | Tse-Wen Chang, Ph.D. 張子文 President, Immunwork, Inc. 免疫功坊股份有限公司董事長 |
9:50-10:30 | Development of Universal Vaccine | Chi-Huey Wong, Ph.D. 翁啟惠 The Scripps Research Institute and Academia Sinica |
| 10:30-10:40 | Break | |
10:40-11:20 | Medicines from the central molecule of the ‘central dogma’: mRNA drugs and vaccines | Örn Almarsson, Ph.D. Principal of AfiRx, LLC |
11:20-12:00 | Bispecific Antibody: Sixty Years of Journey from Concept to Medicine | Herren Wu 吳和仁 President, HW Biologics Consulting, LLC |
11:50-13:00 | Lunch |
|
13:00-13:10 | 3rd meeting of the 3rd TAA General Assembly | Chung-hsiun Wu, Ph.D. 吳忠勳 President, DCB/Chairman, TAA Chih-Jung Chang, Ph.D. 張志榮 COO, EirGenix Inc./Secretary General, TAA 台康生技股份有限公司營運長/台灣抗體協會秘書長 |
13:10-13:20 | Moderator | Karen Wen, Ph.D. 溫國蘭 COO, GenomeFrontier Therapeutics Inc. 先驅生技股份有限公司營運長 |
13:20-14:00 | Adoptive T Cell Therapy of Cancer: First Principles for Lasting Responses | Cassian Yee, M.D. 余嘉誠 Professor, Division of Cancer Medicine |
14:00-14:30 | Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using qCART, the Quantum pBac-based CAR-T system | Sareina Chiung-Yuan Wu, Ph.D 吳瓊媛 CEO, GenomeFrontier Therapeutics Inc. 先驅生技股份有限公司執行長 |
14:30-15:00 | Break |
|
15:00-15:30 | Site-specific conjugation of cytotoxic drug bundles for homogeneous ADCs with high DAR of 6, 8, or 10 | Hsing-Mao Art Chu, Ph.D 朱鑫懋 Vice President of R&D, Immunwork, Inc. 免疫功坊股份有限公司研發副總經理 |
15:30-16:50 | Panel Discussion: Extended Application of Antibody
| Moderator: Han-Chung Wu, Ph.D吳漢忠主任 Director, Biomedical Translation Research Center (BioTReC), Academia Sinica Panelist: Chung-Hsiun Wu, Ph.D. 吳忠勳 台灣抗體協會理事長/生物技術開發中心執行長 Tse-Wen Chang, Ph.D. 張子文 免疫功坊股份有限公司董事長 Karen Wen, Ph.D. 溫國蘭 先驅生技股份有限公司營運長 Lee-Cheng Liu, Ph.D. 劉理成 台康生技股份有限公司創辦人暨總經理 Li-Chuan Hsu, Ph.D. 徐麗娟 財團法人醫藥品查驗中心代理執行長 James Chih-Hsin Yang, MD, Ph.D. 楊志新 國立臺灣大學醫學院附設醫院癌醫中心分院院長 Chiun Hsu, MD, Ph.D. 許 駿 臺大癌醫中心醫院腫瘤內科部/教學研究部主任 Chia-Chi (Josh) Lin, MD, Ph.D. 林家齊 臺大醫院腫瘤醫學部醫師 |
16:50-17:00 | Closing Remarks Election Results Announcement | Chung-Hsiun Wu, Ph.D. 吳忠勳 President, DCB/Chairman, TAA |
